CTOs on the Move

Taiga Biotechnologies Inc

www.taigabiotech.com

 
Taiga Biotechnologies is a privately-held developer of novel therapies for complex diseases including cancers, infectious agents such as HIV and influenza, and hematologic conditions.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Taiga Biotechnologies Inc raised $12M on 06/03/2015

Similar Companies

Ibis Biosciences a Division of Abbott

Ibis Biosciences a Division of Abbott is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Memphis Bio Works

Memphis Bio Works is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dyno Therapeutics

Dynotx.com provides cutting-edge sales and marketing tools for small and medium-sized businesses. Their services include web design, social media management, advertising, and SEO optimization. They aim to help businesses grow and succeed online by prov...

Angion

Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion`s lead product candidate, ANG-3777, is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF) to activate the HGF/c-Met pathway, which has a central role in tissue repair and organ recovery. Enrollment is ongoing in a placebo-controlled Phase 3 registration trial examining the efficacy of ANG-3777 in reducing the severity of transplant-associated acute kidney injury, also known as delayed graft function, in patients at risk for kidney dysfunction. ANG-3777 is also in a Phase 2 clinical trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass. Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for a variety of chronic fibrotic diseases sharing similar underlying disease-driving pathways identified and targeted using a precision-medicine approach.

Aerovate Therapeutics

Aerovate Therapeutics is a biotechnology company focused on developing drugs for rare cardiopulmonary disease.